Edition:
United States

Matthias Blamont

Jeff Mason is a White House Correspondent for Reuters and the 2016-2017 president of the White House Correspondents’ Association. He was the lead Reuters correspondent for President Barack Obama's 2012 campaign and interviewed the president at the White House in 2015. Jeff has been based in Washington since 2008, when he covered the historic race between Obama, Hillary Clinton and John McCain. Jeff started his career in Frankfurt, Germany, where he covered the airline industry before moving to Brussels, Belgium, where he covered the European Union. He is a Colorado native, proud graduate of Northwestern University and former Fulbright scholar.

Twitter handle: @jeffmason1

Dec 13 2017

France's Sanofi pins hopes on new drugs after setbacks

PARIS Sanofi's promising pipeline of experimental drugs can help it overcome setbacks including the low uptake of a new cholesterol treatment and concerns about a dengue vaccine, the French pharmaceuticals group said on Wednesday.

Dec 12 2017

Sanofi investors hungry for drug progress and deal news

PARIS Sanofi still needs to convince markets it can deliver on an exciting and sustainable growth path as it contends with fresh difficulties in its vaccines arm and looks set for another gloomy year in diabetes, investors told Reuters.

Nov 02 2017

Sanofi takes gloomy view of diabetes drug sales

PARIS French drugmaker Sanofi disappointed investors with a more gloomy forecast for its struggling diabetes business on Thursday, while quarterly net income also slipped.

Oct 24 2017

Essilor confident on Luxottica deal despite EU probe

PARIS French eyewear group Essilor said on Tuesday it was confident of securing European Union approval for its $54 billion merger with Italian peer Luxottica after the EU launched a full-scale probe into its impact on competition.

Oct 12 2017

Sanofi boosts vaccines business with 170 million euro investment

VAL-DE-REUIL, France Sanofi on Thursday expressed confidence in the growth of its influenza vaccines after committing to invest 170 million euros to expand its manufacturing facility at Val-de-Reuil in north-western France.

Oct 06 2017

EU should take advantage of drop in migrant influx: OECD'S Gurria

PARIS European Union countries should take advantage of a slowdown in the flow of migrants from Africa and the Middle East to devise a more coherent approach to a crisis that has strained relations between member states, the head of the OECD said on Friday.

Sep 26 2017

Pregnant women still unaware of epilepsy drug risks: EMA hearing

PARIS More than three decades after links emerged between Sanofi's epilepsy drug valproate and birth defects, many pregnant women remain unaware of the risks, patients, doctors and researchers said on Tuesday.

Sep 15 2017

France's Neovacs takes on GSK and AstraZeneca in battle to treat lupus

PARIS French biotech company Neovacs is confident that its experimental drug to treat lupus could grab significant market share from standard treatments of the auto-immune disease, its chief executive said.

Jul 31 2017

Sanofi raises outlook but key eczema drug disappoints investors

PARIS Sanofi raised its 2017 earnings forecast on the back of strong growth in the second quarter but investors were disappointed with sales of key new eczema drug Dupixent, developed with U.S partner Regeneron Pharmaceuticals .

Jul 26 2017

Human Rights Watch: French police use excessive force on Calais migrants

PARIS Human Rights Watch pressed France on Wednesday to end what it described as recurrent police violence against migrants in the northern town of Calais, where hundreds have returned despite the demolition of a sprawling camp once known as "the jungle". | Video

Markets

  • U.S.
  • Europe
  • Asia
  • Sectors

Sector Summary